MedPath

Sesen Bio, Inc.

Sesen Bio, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2010-01-01
Employees
1
Market Cap
-
Website
https://sesenbio.com

Clinical Trials

5

Active:0
Completed:2

Trial Phases

3 Phases

Phase 1:1
Phase 2:3
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (60.0%)
Phase 1
1 (20.0%)
Phase 3
1 (20.0%)

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

Phase 3
Completed
Conditions
Bladder Cancer
First Posted Date
2015-05-20
Last Posted Date
2023-07-24
Lead Sponsor
Sesen Bio, Inc.
Target Recruit Count
133
Registration Number
NCT02449239

Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin

Phase 1
Terminated
Conditions
Neoplasms, Glandular and Epithelial
Interventions
First Posted Date
2007-06-04
Last Posted Date
2023-03-23
Lead Sponsor
Sesen Bio, Inc.
Target Recruit Count
15
Registration Number
NCT00481936
Locations
🇬🇪

Chemotherapy and Immunotherapy clinic Medulla, Tbilisi, Georgia

🇷🇺

Blokhin Cancer Research Centre, Department of Chemotherapy and Combined therapy, Moscow, Russian Federation

🇷🇺

Blokhin Cancer Research Centre, Department of Clinical Pharmacology and Chemotherapy, Moscow, Russian Federation

and more 3 locations

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Phase 2
Completed
Conditions
Bladder Cancer
Bladder Tumors
Urinary Bladder Cancer
Bladder Neoplasms
Interventions
First Posted Date
2007-04-19
Last Posted Date
2020-05-12
Lead Sponsor
Sesen Bio, Inc.
Target Recruit Count
46
Registration Number
NCT00462488
Locations
🇺🇸

Southeastern Research Group, Inc., Tallahassee, Florida, United States

🇺🇸

Johns Hopkins Medical Institutions, Baltimore, Maryland, United States

🇺🇸

Lawrenceville Urology, Lawrenceville, New Jersey, United States

and more 18 locations

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Phase 2
Terminated
Conditions
Neoplasms, Squamous Cell
Carcinoma, Squamous Cell
Carcinoma, Squamous Cell of Head and Neck
Head and Neck Neoplasms
Head and Neck Cancer
Mouth Neoplasms
Interventions
First Posted Date
2006-12-18
Last Posted Date
2015-12-23
Lead Sponsor
Sesen Bio, Inc.
Target Recruit Count
165
Registration Number
NCT00412776
Locations
🇦🇷

Hospital Italiano Regional del Sur, Bahia Blanca, Argentina

🇦🇷

Hospital Municipal de Agudos Leonidas Lucero, Bahia Blanca, Argentina

🇦🇷

Centro de Estudio y Tratamiento de las Enfermedades Neoplasicas (CETEN), Buenos Aires, Argentina

and more 119 locations

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

Phase 2
Terminated
Conditions
Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Carcinoma, Squamous Cell
Mouth Neoplasms
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Interventions
First Posted Date
2006-01-04
Last Posted Date
2015-12-23
Lead Sponsor
Sesen Bio, Inc.
Target Recruit Count
15
Registration Number
NCT00272181
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

UCLA Medical Center, Los Angeles, California, United States

and more 16 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.